Clinical Trial Update: Macular Edema Incidence/Severity Reduction With Nevanac [Phase 3]

View source ↗

Summary

A Phase 3 trial of Nevanac (nepafenac) in diabetic retinopathy aimed at reducing macular edema incidence and severity was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• Nevanac (nepafenac)

Snippet

Sponsor: Alcon Research | Conditions: Diabetic Retinopathy | Phase 3 | Status: TERMINATED